Kiro Grifols

What Kiro Grifols does

Kiro Grifols S.L. is a Spanish medical technology company specializing in robotic and automated compounding systems for hospital pharmacy IV preparation. Originally established in 2010 as Kiro Robotics SL, a spin-off from the Mondragon Corporation, the company was acquired by global healthcare conglomerate Grifols in 2014 and rebranded as Kiro Grifols S.L. The company is headquartered in Arrasate-Mondragón in the Basque Country and operates as part of Grifols' inclusiv portfolio of integrated IV compounding technology, software, and service solutions.

Kiro Grifols' product portfolio addresses both hazardous and non-hazardous sterile compounding through five core offerings: KIRO Oncology (robotic system with two robotic arms, gravimetric verification, and self-cleaning for hazardous drug preparation), KIRO Fill (high-throughput automated device for non-hazardous preparations with ISO 5 aseptic environment), Gri-fill (semi-automatic system for batch and patient-specific production), KIRO Isolator (VHP sterilization robotic compounding system), and KIRO Link (web-based workflow management software with HL7-based HIS integration, KIRO Analytics, digital training, and the KIRO Network community). Systems comply with USP <797>, USP <800>, GMP, ISO 5, IEC 61010, and IEC 61326-1 certifications.

The company generates revenue through direct enterprise sales of capital equipment to hospital pharmacies worldwide, supplemented by multi-year service contracts covering deployment, qualification, periodic maintenance, airflow certifications, and dosing accuracy tests. Distribution leverages Grifols' commercial infrastructure spanning 110+ countries, with active sales engagement at major industry conferences including EAHP, ASHP Midyear, and Arab Health. Named customers include leading cancer centers and academic hospitals across Ireland, France, Canada, the United States, Spain, South Korea, and the Netherlands.

Name

Kiro Grifols

Legal name

Kiro Grifols, S.L.

Website

https://kirogrifols.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Kiro Grifols develops robotic and automated compounding systems for hospital pharmacy IV preparation, serving oncology and sterile compounding departments globally as a subsidiary of Grifols within the inclusiv portfolio.

Ownership category

akta.pro rank

Product category

Hospital Pharmacy Sterile Compounding Automation

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Compounding Pharmacy & Sterile Prep Workflow Systems (HLACAKAM)

akta.pro secondary industry

Pharmacy Information Systems (PIS) & Dispensing Workflow (HLACAKAC)

Keywords

• Sterile IV compounding
• Robotic pharmacy automation
• Chemotherapy preparation systems
• Aseptic compounding devices
• Pharmacy workflow software

Headquarters

HQ city

Arriate

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Robotic Compounding Hardware: Sale of robotic compounding systems (KIRO Oncology, KIRO Fill, Gri-fill, KIRO Isolator) which are major capital equipment investments for hospital pharmacies. Systems include deployment, qualification, and periodic maintenance services.
2. Software and Services: KIRO Link software for workflow management, analytics, training, and service desk. Ongoing maintenance, qualification, and periodic maintenance services for deployed systems.
3. Professional Services: Deployment, qualification, and ongoing maintenance services. Includes dosing accuracy tests, airflow certifications, USP <797> compliance support.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Kiro Grifols designs, manufactures and sells robotic and automated compounding systems (KIRO Oncology, KIRO Fill, Gri-fill, KIRO Isolator) plus the KIRO Link workflow management software for hospital pharmacies. The systems automate the sterile compounding of hazardous (e.g., chemotherapy/oncology) and non-hazardous IV medications, combining robotic arms, gravimetric verification, barcode/RFID identification and HIS/EMR integration, and are sold with deployment, qualification and maintenance services.

Product overview

Kiro Grifols is part of the inclusiv portfolio, a comprehensive IV compounding portfolio of integrated technology, software, and service solutions designed to enhance patient safety in sterile compounding environments. The company's product portfolio includes: KIRO Oncology (robotic compounding system for hazardous drug preparation), KIRO Fill (automated compounding device for non-hazardous sterile preparations), Gri-fill (semi-automatic compounding system for batch and patient-specific production), KIRO Isolator (VPH sterilization robotic compounding system), and KIRO Link (web-based pharmacy workflow management software that integrates all devices). Together, these products provide end-to-end solutions for hospital pharmacy IV compounding from automated preparation to workflow management and analytics.

Differentiator

Problem solved

Functional benefit

Products and services

• KIRO Oncology Robotic compounding system that automates the sterile preparation of hazardous drugs (e.g., chemotherapy/oncology IV medications) for hospital pharmacies. Features two robotic arms, a 12-position vial carousel, gravimetric verification, barcode readers, cameras, enclosed self-cleaning, HIS interface and CSTD compatibility, designed to improve dosing accuracy, sterility and staff protection.
• KIRO Fill Automated compounding device that produces non-hazardous compounded sterile preparations (IV admixtures, syringes, infusion bags) for hospital pharmacies. Features parallel automated units, gravimetric control, RFID tracking, barcode scanning, ISO 5 aseptic environment with HEPA H14 filtration, automatic capping, simultaneous loading/unloading/compounding and HIS integration in a compact footprint.
• Gri-fill Semi-automatic compounding system for batch and patient-specific production of both non-hazardous and hazardous compounded sterile preparations. Uses volumetric and peristaltic pump dosing, performs in-process checks and validation, supports reconstitution and diluent withdrawal, fits inside a biosafety cabinet or isolator, manages multiple final container types and integrates with hospital information systems.
• KIRO Isolator Robotic compounding system that combines vaporized hydrogen peroxide (VHP) sterilization with robotic compounding to provide automated aseptic processing. Includes material sterilization in an entry airlock, a preparation bay for up to 10 infusion bags, a syringe capping station and physical isolation of operators from hazardous drugs to support USP <800> compliance.
• KIRO Link Web-based pharmacy workflow management software that connects Kiro Grifols compounding devices with hospital information systems. Provides bidirectional HL7 HIS integration, a production management dashboard, drug master data management, KIRO Analytics productivity reporting, a digital training and competency platform, KIRO Network user community and a customer service desk.

Quantifiable outcome

• KIRO Oncology self-cleaning system achieves 99.8% or greater decontamination efficacy for nine common cytotoxic drugs (5-fluorouracil, ifosfamide, cyclophosphamide, gemcitabine, etoposide, methotrexate, paclitaxel, docetaxel, carboplatin)
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

Partnerships

One partnership is on record.

• GrifolscoreStrategic or Co-development PartnerGrifols acquired Kiro Robotics SL in 2014 and rebranded it as Kiro Grifols SL. All Kiro products are part of inclusiv portfolio and integrated into Grifols Healthcare Solutions. Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving health and well-being in more than 110 countries.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Fresenius Kabi: Fresenius Kabi supplies IV drugs, infusion devices, and compounding-related consumables to the same hospital pharmacy customers that purchase KIRO systems, making it a relevant adjacent player in sterile compounding workflows.
• Omnicell: Omnicell is a dominant player in pharmacy and medication management automation; its central pharmacy IV compounding and inventory solutions overlap with the hospital pharmacy segment Kiro serves, even though its core strength is unit-dose dispensing automation.
• B. Braun: B. Braun offers compounding and IV admixture solutions (e.g., APEX compounding system) targeting hospital pharmacies; as a broad medical device incumbent with global sales force, it is comparable on customer base and pharmacy compounding workflow, though not specialized in robotics.

Direct peers

• ICU Medical: ICU Medical's pharmacy compounding and IV workflow solutions (including legacy Hospira/ICU technologies) compete directly with Kiro's automated compounding portfolio for hospital pharmacy automation budgets.
• Baxter International (DoseEdge): Baxter's DoseEdge is a leading pharmacy IV workflow and compounding management system that competes with KIRO Link and serves the same hospital pharmacy dosing/compounding use cases that Kiro targets with both hardware and software.
• ARxIUM (RIVA): ARxIUM's RIVA system is one of the most established fully automated robotic IV compounding platforms for hazardous and non-hazardous sterile preparations; it competes head-to-head with KIRO Oncology and KIRO Fill for hospital pharmacy automation contracts.

Regional players

• Yuyama Co., Ltd. Yuyama is a major Japanese pharmacy automation manufacturer with compounding and dispensing equipment; comparable on technology and use case, but its primary geographic footprint is Asia, distinct from Kiro's Europe-centric sales footprint.

Emerging players

• Health Robotics (now part of Loccioni / independent): Health Robotics developed i.v.STATION, an early robotic IV compounding system, putting it in direct product/technology competition with KIRO Oncology for hazardous drug preparation automation in hospital pharmacies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kiro_robotics

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kiro Grifols